Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo offers hope for bladder cancer patients who failed standard treatment

NCT ID NCT06388720

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 23 times

Summary

This study tests whether giving two chemotherapy drugs (mitomycin-C and gemcitabine) directly into the bladder can control high-risk bladder cancer that has not responded to the standard BCG therapy. About 82 adults with this type of cancer will receive the treatment and be monitored for cancer return or spread. The goal is to find a safer, effective option to delay or avoid bladder removal surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center

    RECRUITING

    Goyang-si, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.